TriSalus Life Sciences, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mary T. Szela
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 6272 West 91st Avenue Westminster CO United States of America 80031
- IPO Date
- Feb 8, 2021
- CIK
- 0001826667
- Website
- trisaluslifesci.com
- Similar Companies
- Business
- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) develops and commercializes oncology-focused medical technologies, including proprietary drug delivery systems and investigational immuno-oncology therapeutics, to improve outcomes for patients with difficult-to-treat solid tumors such as liver and pancreatic cancers; its Pressure-Enabled Drug Delivery (PEDD) infusion systems overcome intratumoral pressure and immunosuppression barriers to enhance therapy penetration and efficacy. The company offers the commercial-stage TriNav Infusion System with SmartValve technology for transarterial radioembolization and chemoembolization procedures in liver cancer and metastases; the TriNav FLX Infusion System, launched in 2025 with enhanced trackability and flexibility for tortuous vessels; the TriNav XP Infusion System; TriNav LV and TriGuide for larger vessels; and the investigational Pancreatic Retrograde Venous Infusion device in Phase 1 trials for locally advanced pancreatic cancer. It also advances nelitolimod (SD-101), an investigational immunotherapy in Phase 1/2 trials for hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, and uveal melanoma liver metastases, often combined with checkpoint inhibitors. Founded in 2009 and headquartered in Westminster, Colorado, with additional facilities in Bannockburn, Illinois, TriSalus primarily serves interventional radiologists, oncologists, and healthcare providers in the United States through its direct sales force; the company completed a business combination with MedTech Acquisition Corporation in 2023 to support commercialization and trials, drew down $10 million in February 2025 under a $50 million OrbiMed credit agreement upon hitting a $30 million revenue milestone, raised $22 million in a private placement in early 2025, and continues strong revenue growth with reaffirmed 50% guidance amid recent product expansions.
Company News
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
TriSalus Life Sciences Q2 Earnings Call Highlights
TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript
TriSalus Life Sciences Reports Second Quarter 2026 Results
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer